President and CEO of the Muscular Dystrophy Association (MDA), Lynn O’Connor Vos, discusses the work that the organization is doing to fund research for neuromuscular diseases. MDA is the largest source of funding for neuromuscular disease research outside the federal government and has committed more than $1 billion in funding since its inception. Click here to find out more about the MDA Conference.
Flexion CEO Dr. Mike Clayman, discusses the company’s inflection year ahead, gene therapy, the importance of non-opioid options for people suffering from pain, and attracting/retaining talent in biotech/biopharma scene. Flexion is focused on advancing local therapies for patients with musculoskeletal disorders. The company’s non-opioid pain treatment, Zilretta, is an FDA approved intra-articular (“in the joint”) injection for pain due to osteoarthritis (OA) of the knee.
Dr. William Sandborn, University of California San Diego, discusses his presentation of the pivotal phase 3 data for STELARA® (ustekinumab) as maintenance therapy in patients with moderate to severe ulcerative colitis (UC), at the European Crohn’s & Colitis Organisation Annual Meeting (ECCO) 2019.
Dr. Jennifer Bateman, National VP of Youth Development for Boys & Girls Clubs of America and Dr. Laura Herrerra Scott VP of Medicaid Clinical Operations for Anthem, talk about the health program “Triple Play” that focuses on developing a youth’s mind, body and soul.
Jennifer and Dan Digmann, a married couple, discuss their life while both living with MS.
Returning guest, Vanessa Rose Bisceglie, discusses the new law changes within MACRA (Medicare Access and CHIP Reauthorization Act of 2015) and how physicians can stay in compliance and earn the highest bonus in their medicare payment. She also discusses the telehealth care management services that they offer that assists patients between office visits.
Dr. Kimberly Smith, MD. MPH, head of global research and medical strategy for ViiV Healthcare discusses 48 week data from the ATLAS (Antiretroviral Therapy as Long-Acting Suppression) and FLAIR (First Long-Acting Injectable Regimen) phase III studies of the 2 drug combination of cabotegravir and rilpivirine for the treatment of HIV-1.
ElectroCore co-founder and senior executive advisor of Medical and Government Affairs, Dr. Peter Staats discusses new survey results that revealed a significant underutilization of non-drug treatment options for migraine among female patients and health care providers (HCPs). This survey showed that only 8% of HCPs reported treatment of patients with non-drug therapy.
Dr. Robert Hauser, Director at Parkinson’s Disease and Movement Disorders Center in Tampa, discusses the signs and symptoms of Parkinson’s disease and OFF periods (a time when symptoms recur while on baseline medication), and ON periods (when symptoms are controlled) as well as ways to help manage them with treatment options.
Dan Roberts, AMD Patient, Advocate & Founding Director of MD Support, Inc. and the International Macular Degeneration Support Group talks about his passion for educating others about AMD (Age-related macular degeneration). He also talks about how the Ellex 2RT®, a first of its kind laser treatment for macular degeneration, can improve the quality of life for patients with AMD and offer a solution to the burden of care placed on payers and society resulting from AMD.